Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
Wall Street Hits New Highs as U.S.-Iran Ceasefire Talks Boost Market Sentiment 
Oil Prices Jump After New U.S. Strikes on Iran Raise Supply Concerns 
Canada and Germany Advance Major LNG Supply Partnership 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
Iran-U.S. Nuclear Talks Remain Unresolved as Strait of Hormuz Risks Keep Markets on Edge 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
U.S. Launches New Strikes on Iran as Trump Signals Peace Deal Uncertainty 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Celltrion revealed the results of its phase 3 clinical trial for its COVID-19 treatment drug called Regkirona. The final testing was said to have yielded good results, and the biopharmaceutical company headquartered in Incheon, South Korea, presented it at a conference in Europe.
The effectiveness of Celltrion’s Regkirona
As per The Korea Herald, Celltrion said on Tuesday, July 13, that its anti-body COVID-19 treatment can reduce the risk of the infection from becoming a severe case by 70%. Based on the final round of tests, the high-risk groups showed a reduced progression rate to severe infection by 72%.
The patients who were administered the Regkirona treatment were able to recover from COVID-19 in just 8.4 days. This was said to be 4.9 days faster compared to patients who used placebo treatment and recovered for 13.3 days.
For high-risk groups, Celltrion’s anti-body treatment helped patients recover for 9.3 days which is likewise faster by 4.7 days compared to the placebo group who recovered in 14 days. Moreover, the Korean biopharmaceutical company further discovered that its treatment significantly reduced viral titers in patients after they were given Regkirona.
Most importantly, there were no severe adverse effects or allergic reactions detected. Besides the mild and temporary reactions from patients, there have been no reports of severe responses to the drug. While the results of the trial were good, Celltrion is still testing if the treatment is also effective against other variants of COVID-19, such as the delta.
The presentation in Europe
The results of Celltrion’s antibody COVID-19 treatment were presented in Europe by Oana Sandulescu, who is an associate professor at Carol Davila University of Medicine and Pharmacy. She shared the results during the 31st European Congress of Clinical Microbiology and Infectious Diseases that was held online from July 9 to 12, according to The Korea Economic Daily.
Sandulescu attested that Regkirona significantly lowered the rate of progression for severe coronavirus infection symptoms and hastened the recovery time too. In any case, the associate professor took part in the clinical trial of Regkirona that was conducted from January to April with 1,315 participants from 13 countries.
